健世科技-B(09877.HK):於2023年美國經導管心血管治療學大會上發佈LUX-VALVE PLUS多中心臨牀試驗的結果
格隆匯10月19日丨健世科技-B(09877.HK)發佈公吿,在2023年美國經導管心血管治療學大會(“TCT”)上,復旦大學附屬中山醫院葛均波教授攜其團隊將就LuXValve Plus多中心臨牀試驗的結果進行報吿。LuX-Valve Plus為公司自主開發的第二代經頸靜脈三尖瓣置換系統。
2023年經導管心血管治療學大會將於2023年10月23日至10月26日在美國加利福尼亞州三藩市舉行。經導管心血管治療學大會為心血管研究基金會(“CRF”)舉辦的年度科學研討會,為世界上規模最大及最具影響力的專注心血管介入醫學的全球會議。LuX-Valve Plus於歐洲CE認證臨牀試驗、美國FDA註冊臨牀試驗及亞太地區收費同情救治使用均在積極推進中。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.